DCP/PREVENT-funded Project Presentations at the 2022 AACR Annual Meeting

Date Posted: 

Friday, April 1, 2022

April 8-13, 2022

DCP/PREVENT-funded Project Presentations

Session OPO.IM01.01 - Tumor Immunobiology
5631 - Immunomodulatory activity of sulindac plus erlotinib for colon cancer prevention in familial adenomatous polyposis
Presenter/Authors
Chakrapani Tripathi, Roderick H. Dashwood. Texas A&M Institute of Biosciences and Technology, Houston, TX
https://www.abstractsonline.com/pp8/#!/10517/presentation/18665
PREVENT-funded Contract 75N91019D00021, Task Order 75N91019F00130

Session OPO.IM02.01 - Preclinical Immunotherapy
5562 - Development of a TERT-specific peptide/adjuvant vaccine in C57BL/6 mice
Presenter/Authors
Jason D. Marshall, Yurong Song, Hamid Zarkesh, Rebecca L. Matthews, Chelsea Sanders, Simone Difilippantonio, Ligia A. Pinto, Shizuko Sei, Robert H. Shoemaker. Frederick National Laboratory for Cancer Research, Frederick, MD, Frederick National Laboratory for Cancer Research, Frederick, MD, National Cancer Institute, Bethesda, MD
https://www.abstractsonline.com/pp8/#!/10517/presentation/17782
Not PREVENT-funded

DCP/PREVENT-funded Poster Presentations

Session PO.PR01.02 - Preclinical Prevention, Early Detection, and Interception 2
706 / 1 - Efficacy evaluation of BR-9001, a SMEDDS formulation of 3,3’-diindolylmethane, as an inhibitor of preneoplastic and neoplastic lesion development in the prostate of Hi-Myc mice
Presenter/Authors
Genoveva Murillo, Gina Qualter, Xinjian Peng, Miguel Muzzio, Elizabeth R. Glaze, Altaf Mohammed, Maarten C. Bosland, David L. McCormick. IIT Research Institute, Chicago, IL, IIT Research Institute, Chicago, IL, National Cancer Institute, Rockville, MD, University of Illinois at Chicago, Chicago, IL
https://www.abstractsonline.com/pp8/#!/10517/presentation/14172
PREVENT-funded Contract HHSN261201500042I, Task Order HHSN26100003

Session PO.PR01.02 - Preclinical Prevention, Early Detection, and Interception 2
715 / 10 - Targeting the mTOR pathway for the prevention of er-negative breast cancer
Presenter/Authors
Abhijit Mazumdar, Jamal Hill, William Tahaney, Yanxia Ma, Alejandro Contreras, Shizuko Sei, Altaf Mohammed, Powel Brown. UT MD Anderson Cancer Center, Houston, TX
https://www.abstractsonline.com/pp8/#!/10517/presentation/14198
PREVENT-funded Contract HHSN261201500018I, Task Order HHSN26100006

Session PO.PR01.02 - Preclinical Prevention, Early Detection, and Interception 2
719 / 14 - Preclinical testing of CD73 inhibitors for pancreatic cancer immunoprevention
Presenter/Authors
Kanchan Singh, Vidhi Chandra, Lincoln Ballew, Tingting Mills, Erika Y. Faraoni, Trent Clark, Lana A. Vornik, Michelle I. Savage, Holger K. Eltzschig, Altaf Mohammed, Shizuko Sei, Powel H. Brown, Florencia McAllister, Jennifer Bailey-Lundberg. The University of Texas Health Science Center at Houston, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD
https://www.abstractsonline.com/pp8/#!/10517/presentation/14203
PREVENT-funded Contract 75N91019D00021, Task Order 75N91020F00002

Session LBPO.PSPR01 - Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception
LB164 / 8 - Combination of naproxen and a novel longer acting eicosapentaenoic acid analogue provide synergistic tumor protection in polyposis in rat colon (PIRC) model
Presenter/Authors
Ryan Beach, Daniel W. Rosenberg, Altaf Mohammed. Center for Molecular Oncology, UConn Health, Farmington, CT, Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD
https://www.abstractsonline.com/pp8/#!/10517/presentation/20107
PREVENT-funded Contract 75N91019D00019, Task Order 75N91019F00132

Session LBPO.PSPR01 - Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception
LB165 / 9 - Preclinical evaluation of carnosic acid (CA) and rosemary extract standardized to 40% carnosic acid (RE40CA) for the prevention of invasive breast cancer
Presenter/Authors
Yan Hong, Aditi Rastogi, Aryamitra Banerjee, Brandon L. Plattner, Matthew Lindeblad, Alexander V. Lyubimov, Timothy Fields, Seema A. Khan, Altaf Mohammed, Jeremy J. Johnson, Fariba Behbod. University of Kansas Medical Center, Kansas City, KS, The University of Illinois at Chicago, Chicago, IL, Kansas State University, Manhattan, KS, Northwestern University, Chicago, IL, National Cancer Institute, Bethesda, MD
https://www.abstractsonline.com/pp8/#!/10517/presentation/20108
PREVENT-funded Contract 75N91019D00016, Task Order 75N91020F00001

DCP Staff Sessions

Session APRV02 - Can Precancer Early Detection Become a Reality?
Philip E. Castle - What is “precancer,” should we detect it, and if so, under what circumstances?

Session NIH06 - NCI Opportunities in Funding: Cancer Prevention and Control Clinical Trials Planning Grant Program
Brandy Heckman-Stoddard, Moderator and Presenter

Session SS03 Networking Hubs
Philip E. Castle - Cancer Prevention and Interception

DCP/PREVENT-Related

Possible additional analyses on samples from PREVENT Contract HHSN261201500038I, Task Order HHSN26100006
Session PO.CL11.08 - Biomarkers Predictive of Therapeutic Benefit 3
2783 / 17 - Increased tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in normal colonic mucosa with imipridone ONC201/TIC10 treatment: A potential biomarker for chemoprevention studies
Presenter/Authors
Alexander G. Raufi*, Arielle De La Cruz*, Andrew George, Sean Hacking, Venkateshwar Madka, Varun Prabhu, Howard Safran, Lanlan Zhou, Dean Brenner, Chinthalapally V. Rao, Wafik S. El-Deiry. Brown University, Providence, RI, University of Oklahoma Health Sciences Center, Oklahoma, OK, Chimerix, Durham, NC, University of Michigan, Ann Arbor, MI